CrossAssetDataThe Company File
···
CAI

Caris Life Sciences, Inc.

Caris Life Sciences, Inc. is classed by the SEC under Services-Medical Laboratories (industry code 8071), based in Irving, TX. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $812 million and a loss of $538 million (its filed statements).

Usage business Services-Medical Laboratories Irving, TX filings since 2024 6 of 9 filed, 3 estimated
Ask the desk about CAI → Compare CAI with FLGT → Price chart on TradingView ↗ Full EDGAR file ↗ Watch CAI →

Sector peers: FLGTVCYTBLLNGH

6.0/10headline grade
vs its business-model standard
5.8/10past 6.8/10present 5.2/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8071, Services-Medical Laboratories); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.0 out of ten, 6 of 9 metrics filed and 3 estimated: past 5.8 out of ten, present 6.8 out of ten, future 5.2 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 7.8 out of ten. No warning events in its filings since 2024. 78th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 7.1 out of ten. +62.8% a year over 3 filed years; profitable in 0 of 3. 71st percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 0.2 out of ten. CrossAssetData estimate 0.2/10, confidence 35 of 100 (one part). 2nd percentile among 24 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 3.5 out of ten. ROE -12%: lost 12¢ per shareholder dollar. Leverage 49%: owes 49¢ per asset dollar. 35th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 7.7 out of ten. top 23% of 23 in its family; net margin -8.4%. 77th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 9.8 out of ten. CrossAssetData estimate 9.8/10, confidence 35 of 100 (one part). 98th percentile among 22 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Room to expand (future): 5.6 out of ten. top 44% of 23 in its family for room to expand. 56th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 5.4 out of ten. top 46% of 23 in its family for growth drivers. 54th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 4.7 out of ten. CrossAssetData estimate 4.7/10, confidence 20 of 100 (family median). 50th percentile among 20 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.

The filing record

Newest annual report: Form 10-K filed 2026-03-03 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 4, 2026-09-23. Filings on record since 2024. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Molecular Profiling Services 94%, Pharma Research and Development Services 6%. By geography: United States 99%, International 1%. As tagged in its annual report (Form 10-K, filed 2026-03-03).

Who runs it

Halbert, David D (Founder, Chairman, and Chief Executive Officer); Brille, Brian J (Vice Chairman and Executive Vice President); Denton, John Russel (Senior Vice President, General Counsel, and Secretary); Spetzler, David Baxley (President); Power, Luke Thomas (Senior Vice President, Chief Financial Officer, and Chief Accounting Officer); Castleman, Peter M (director); Fredrickson, David Paul (director); Gilliam, Joseph E (director); Halbert, Jon (director); Johansen, Laura I (director); and 5 more. 15 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.